Related Experiment Videos
Future directions for vinorelbine (Navelbine)
1Department of Breast and Gynecologic Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA.
Seminars in Oncology
|April 1, 1995
Summary
Vinorelbine is a new vinca alkaloid effective for metastatic breast cancer treatment. It shows significant response rates as a single agent and in combination therapies, offering a valuable new option.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic breast cancer treatment involves sequential hormone therapy or combination chemotherapy.
- New cytotoxic agents are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of vinorelbine, a novel vinca alkaloid, in treating metastatic breast cancer.
Main Methods:
- Vinorelbine administered intravenously weekly as a single agent.
- Vinorelbine used in front-line chemotherapy combinations with anthracyclines or 5-fluorouracil.
Main Results:
- Single-agent vinorelbine achieved major objective responses in 45% of patients.
- 20% to 30% objective regression observed in patients pre-treated with chemotherapy.
- Combination therapy with vinorelbine showed comparable remission rates, durations, and survival times to standard combinations.
Conclusions:
- Vinorelbine is an effective agent for metastatic breast cancer.
- It represents a valuable addition to the available treatment options.